EDSA Quote, Financials, Valuation and Earnings

Lexaria Bioscience Corp. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of -2178.51%. Edesa Biotech, Inc.'s return on equity of -77.48% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.

Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 643.24%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 450.73%. Given that Edesa Biotech, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe Edesa Biotech, Inc. is more attractive than Lexaria Bioscience Corp..

Edesa Biotech, Inc. has a beta of 0.133, which suggesting that the stock is 86.677% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.888%.

Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is lower than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus 30.03x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of --. Edesa Biotech, Inc.'s return on equity of -77.48% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 643.24%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.52 which suggests that it could grow by 333.91%. Given that Edesa Biotech, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Oncolytics Biotech, Inc..

Edesa Biotech, Inc. has a beta of 0.133, which suggesting that the stock is 86.677% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.

Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of --. Edesa Biotech, Inc.'s return on equity of -77.48% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.

Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 643.24%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $105.58 which suggests that it could grow by 1041.42%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Edesa Biotech, Inc..

Edesa Biotech, Inc. has a beta of 0.133, which suggesting that the stock is 86.677% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.097, suggesting its less volatile than the S&P 500 by 109.676%.

Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.

Edesa Biotech, Inc. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Edesa Biotech, Inc.'s net margin of -867.29%. Edesa Biotech, Inc.'s return on equity of -77.48% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Edesa Biotech, Inc. has a consensus price target of $11.00, signalling upside risk potential of 643.24%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.51 which suggests that it could grow by 31.41%. Given that Edesa Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..

Edesa Biotech, Inc. has a beta of 0.133, which suggesting that the stock is 86.677% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.579%.

Edesa Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Edesa Biotech, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Edesa Biotech, Inc.'s net income of -$2.2M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Edesa Biotech, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech, Inc. is 31.22x versus 443.91x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.